Age

18–any

Sex

ALL

Healthy volunteers

Not accepted

Confirmed diagnosis of PMF, post-PV MF or post-ET MF (WHO)
High-risk, or intermediate-1 and 2 risk, defined by Dynamic International Prognostic System (DIPSS)
ECOG of 0 or 1

Subjects who are positive for p53 mutation (Arm 1)
Prior MDM2 inhibitor therapy or p53-directed therapy (Arm 1)
Prior treatment with any JAK inhibitor
Prior splenectomy
Splenic irradiation within 24 weeks prior to randomization
Prior allogeneic stem-cell transplantation or plans for allogeneic stem-cell transplant
History of major organ transplant
Grade 2 or higher QTc prolongation
Major hemorrhage or intracranial hemorrhage within 24 weeks prior to randomization

Study of KRT-232 or TL-895 in Janus Associated Kinase Inhibitor Treatment-Naïve Myelofibrosis